Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points.

Literature DB >> 12654681

In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points.

Itamar Shalit¹, Yona Shadkchan, Zmira Samra, Nir Osherov.

Abstract

Caspofungin and itraconazole were studied alone and in combination against 31 clinical isolates of Aspergillus spp. according to NCCLS M38-P guidelines. MICs and microscopic minimal effective concentrations (MECs) were recorded, and synergy was calculated by using both end points. Synergy or synergy to additivity was found in 30 of 31 isolates by using MIC end points. With MEC end points no synergy was found and indifference was detected in 26 of 31 strains.

Entities: Chemical Gene

Mesh：

Substances：

Year: 2003 PMID： 12654681 PMCID： PMC152511 DOI： 10.1128/AAC.47.4.1416-1418.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

9 in total

1. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors: Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191

2. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Authors: Sevtap Arikan; Mario Lozano-Chiu; Victor Paetznick; John H Rex
Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191

3. Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens.

Authors: L H Hanson; D A Stevens
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

4. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.

Authors: S P Franzot; A Casadevall
Journal: Antimicrob Agents Chemother Date: 1997-02 Impact factor: 5.191

5. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors: S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191

Review 6. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.

Authors: A H Groll; T J Walsh
Journal: Expert Opin Investig Drugs Date: 2001-08 Impact factor: 6.206

7. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors: William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191

8. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Authors: M B Kurtz; I B Heath; J Marrinan; S Dreikorn; J Onishi; C Douglas
Journal: Antimicrob Agents Chemother Date: 1994-07 Impact factor: 5.191

Review 9. Invasive Aspergillus infections in hematologic malignancy patients.

Authors: Sofia Perea; Thomas F Patterson
Journal: Semin Respir Infect Date: 2002-06

9 in total

25 in total

1. Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae.

Authors: Sarit Markovich; Aya Yekutiel; Itamar Shalit; Yona Shadkchan; Nir Osherov
Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191

Review 2. Combination antifungal therapy.

Authors: Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191

Review 3. Aspergillus infections in transplant recipients.

Authors: Nina Singh; David L Paterson
Journal: Clin Microbiol Rev Date: 2005-01 Impact factor: 26.132

4. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.

Authors: Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maria J Buitrago; Emilia Mellado; Guillermo Garcia-Effron; Juan L Rodriguez-Tudela
Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191

5. In vitro evaluation of antifungal drug combinations against Sarocladium (Acremonium) kiliense, an opportunistic emergent fungus resistant to antifungal therapies.

Authors: Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Deanna Sutton; Josep Guarro
Journal: Antimicrob Agents Chemother Date: 2013-11-18 Impact factor: 5.191

6. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.

Authors: Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Guillermo Garcia-Effron; Laura Alcazar-Fuoli; Emilia Mellado; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal: Antimicrob Agents Chemother Date: 2005-03 Impact factor: 5.191